Bill Text: AZ HB2078 | 2014 | Fifty-first Legislature 2nd Regular | Engrossed
Bill Title: Cancer treatment medications; cost-sharing
Spectrum: Partisan Bill (Republican 1-0)
Status: (Passed) 2014-04-30 - Chapter 255 [HB2078 Detail]
Download: Arizona-2014-HB2078-Engrossed.html
|
Senate Engrossed House Bill |
|
State of Arizona House of Representatives Fifty-first Legislature Second Regular Session 2014
|
|
HOUSE BILL 2078 |
|
|
|
|
AN ACT
amending title 20, chapter 4, article 3, Arizona Revised Statutes, by adding section 20-841.10; amending title 20, chapter 4, article 9, Arizona Revised Statutes, by adding section 20-1057.14; amending title 20, chapter 6, article 4, Arizona Revised Statutes, by adding section 20-1376.05; amending title 20, chapter 6, article 5, Arizona Revised Statutes, by adding section 20-1406.06; relating to health insurance.
(TEXT OF BILL BEGINS ON NEXT PAGE)
Be it enacted by the Legislature of the State of Arizona:
Section 1. Title 20, chapter 4, article 3, Arizona Revised Statutes, is amended by adding section 20-841.10, to read:
20-841.10. Cancer treatment medications; cost‑sharing; definition
A. A contract that is issued, delivered or renewed by a corporation on or after January 1, 2016 and that provides coverage both for cancer treatment medications that are injected or intravenously administered by a health care provider and for patient‑administered cancer treatment medications, including medications that are orally administered or self‑injected, may not require a higher copayment, deductible or coinsurance amount for patient‑administered cancer treatment medications than is required for those cancer treatment medications that are injected or intravenously administered by a health care provider, regardless of the formulation or benefit category.
B. A corporation may not increase copayment, deductible or coinsurance amounts for covered cancer treatment medications that are injected or intravenously administered in order to avoid compliance with subsection A of this section, but may increase copayment, deductible or coinsurance amounts for cancer treatment medications if the increase is applied generally to other medical or pharmaceutical benefits under the contract and is not done to circumvent subsection A of this section.
C. A corporation may not reclassify benefits with respect to cancer treatment medications in a manner that is inconsistent with this section.
D. For the purposes of this section, "cancer treatment medications" means prescription drugs and biologics that are used to kill, slow or prevent the growth of cancerous cells.
Sec. 2. Title 20, chapter 4, article 9, Arizona Revised Statutes, is amended by adding section 20-1057.14, to read:
20-1057.14. Cancer treatment medications; cost‑sharing; definition
A. An evidence of coverage that is issued, delivered or renewed by a health care services organization on or after January 1, 2016 and that provides coverage both for cancer treatment medications that are injected or intravenously administered by a health care provider and for patient‑administered cancer treatment medications, including medications that are orally administered or self‑injected, may not require a higher copayment, deductible or coinsurance amount for patient‑administered cancer treatment medications than is required for those cancer treatment medications that are injected or intravenously administered by a health care provider, regardless of the formulation or benefit category.
B. A health care services organization may not increase copayment, deductible or coinsurance amounts for covered cancer treatment medications that are injected or intravenously administered in order to avoid compliance with subsection A of this section, but may increase copayment, deductible or coinsurance amounts for cancer treatment medications if the increase is applied generally to other medical or pharmaceutical benefits under the evidence of coverage and is not done to circumvent subsection A of this section.
C. A health care services organization may not reclassify benefits with respect to cancer treatment medications in a manner that is inconsistent with this section.
D. For the purposes of this section, "cancer treatment medications" means prescription drugs and biologics that are used to kill, slow or prevent the growth of cancerous cells.
Sec. 3. Title 20, chapter 6, article 4, Arizona Revised Statutes, is amended by adding section 20-1376.05, to read:
20-1376.05. Cancer treatment medications; cost‑sharing; definition
A. A disability insurance policy that is issued, delivered or renewed by a disability insurer on or after January 1, 2016 and that provides coverage both for cancer treatment medications that are injected or intravenously administered by a health care provider and for patient‑administered cancer treatment medications, including medications that are orally administered or self‑injected, may not require a higher copayment, deductible or coinsurance amount for patient‑administered cancer treatment medications than is required for those cancer treatment medications that are injected or intravenously administered by a health care provider, regardless of the formulation or benefit category.
B. A disability insurer may not increase copayment, deductible or coinsurance amounts for covered cancer treatment medications that are injected or intravenously administered in order to avoid compliance with subsection A of this section, but may increase copayment, deductible or coinsurance amounts for cancer treatment medications if the increase is applied generally to other medical or pharmaceutical benefits under the policy and is not done to circumvent subsection A of this section.
C. A disability insurer may not reclassify benefits with respect to cancer treatment medications in a manner that is inconsistent with this section.
D. For the purposes of this section, "cancer treatment medications" means prescription drugs and biologics that are used to kill, slow or prevent the growth of cancerous cells.
Sec. 4. Title 20, chapter 6, article 5, Arizona Revised Statutes, is amended by adding section 20-1406.06, to read:
20-1406.06. Cancer treatment medications; cost‑sharing; definition
A. A group or blanket disability policy that is issued, delivered or renewed by a group or blanket disability insurer on or after January 1, 2016 and that provides coverage both for cancer treatment medications that are injected or intravenously administered by a health care provider and for patient‑administered cancer treatment medications, including medications that are orally administered or self‑injected, may not require a higher copayment, deductible or coinsurance amount for patient‑administered cancer treatment medications than is required for those cancer treatment medications that are injected or intravenously administered by a health care provider, regardless of the formulation or benefit category.
B. A group or blanket disability insurer may not increase copayment, deductible or coinsurance amounts for covered cancer treatment medications that are injected or intravenously administered in order to avoid compliance with subsection A of this section, but may increase copayment, deductible or coinsurance amounts for cancer treatment medications if the increase is applied generally to other medical or pharmaceutical benefits under the policy and is not done to circumvent subsection A of this section.
C. A group or blanket disability insurer may not reclassify benefits with respect to cancer treatment medications in a manner that is inconsistent with this section.
D. For the purposes of this section, "cancer treatment medications" means prescription drugs and biologics that are used to kill, slow or prevent the growth of cancerous cells.
Sec. 5. Short title
This act may be cited as the "Fair Access to Cancer Treatment Act".
